Dupilumab for cancer-associated refractory pruritus

Dupilumab for cancer-associated refractory pruritus

Background: Pruritus can be an intolerable symptom in patients with cancer. Type 2 inflammation, and specifically, the cytokines IL-4, IL-13, and IL-31, play major roles in the itching process. Dupilumab is an antibody against IL-4Rα, which is a common IL-4 and IL-13 receptor subunit. Blocking IL-4...

詳細記述

書誌詳細
主要な著者: Aviv Talmon, MD, Shlomo Elias, MD, PhD, Limor Rubin, MD, Yaarit Ribak, MD, Eyal Ben Dori, MD, Oded Shamriz, MD, Michal Lotem, MD, Irit Adini, PhD, Yuval Tal, MD, PhD
フォーマット: 論文
言語:English
出版事項: Elsevier 2023-08-01
シリーズ:Journal of Allergy and Clinical Immunology: Global
主題:
Oncologic pruritus
chronic pruritus
itch
IL-4
IL-13
IL-31
オンライン･アクセス:http://www.sciencedirect.com/science/article/pii/S277282932300053X

インターネット

http://www.sciencedirect.com/science/article/pii/S277282932300053X

類似資料